The detection of EGFR activating or resistance mutations associated with advanced or metastatic non-small cell lung cancer (NSCLC) allows targeted treatment with first-, second- or third-generation tyrosine kinase inhibitors [1, 2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.